NCT07137494

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

A Phase I Study of MB-CART19.1 Cellular Therapy for Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) Using On- Site Manufacturing With the CliniMACS Prodigy Device

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

Conditions

• Primary Central Nervous System (CNS) Lymphoma
• Secondary Central Nervous System Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	MB-CART19.1 Cellular Therapy	MB-CART19.1 will be infused as a single infusion during an inpatient admission.

Timeline

• Start date: 2025-08-14
• Primary completion: 2028-08-01
• Completion: 2028-08-01
• First posted: 2025-08-22
• Last updated: 2026-03-16

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study